Scholarlink

Key points <p>• Individuals with IBD are at an increased risk of developing certain malignancies, both from disease activity as well as certain immunosuppressive medications.</p> <p>• Withholding some immunosuppressive agents, such as thiopurine, anti-TNF agents, and JAK inhibitors should be considered in patients with active or prior cancers.</p> <p>• Certain anti-neoplastic regimens, such as hormonal deprivation therapy, immune checkpoint inhibitors (ICIs), and pelvic radiation, can increase the risk of IBD flares during cancer treatment.</p> <p>• Decisions regarding cancer treatments and IBD therapy should be individualized and made with cooperation between gastroenterologists and oncologists.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Managing Biologic Therapy and Small Molecule Use in IBD Patients during and after Cancer Diagnosis

  • 期刊论文

  • 发表日期：

    2025年10月8日

查看全文
  • Andrew Eidelberg,
  • Jordan Axelrad

摘要

Key points

• Individuals with IBD are at an increased risk of developing certain malignancies, both from disease activity as well as certain immunosuppressive medications.

• Withholding some immunosuppressive agents, such as thiopurine, anti-TNF agents, and JAK inhibitors should be considered in patients with active or prior cancers.

• Certain anti-neoplastic regimens, such as hormonal deprivation therapy, immune checkpoint inhibitors (ICIs), and pelvic radiation, can increase the risk of IBD flares during cancer treatment.

• Decisions regarding cancer treatments and IBD therapy should be individualized and made with cooperation between gastroenterologists and oncologists.